Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.
Animals
Endothelial Cells
/ metabolism
Female
Gene Deletion
Mammary Neoplasms, Experimental
/ blood supply
Mice
Mice, Transgenic
MicroRNAs
/ genetics
Neoplasm Proteins
/ genetics
Neovascularization, Pathologic
/ genetics
Plasminogen Activator Inhibitor 1
/ genetics
RNA, Neoplasm
/ genetics
Receptor, Transforming Growth Factor-beta Type II
/ deficiency
Transforming Growth Factor beta
/ genetics
Breast cancer
Extracellular matrix
Oncology
Vascular Biology
endothelial cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
11 03 2019
11 03 2019
Historique:
received:
25
06
2018
accepted:
01
02
2019
entrez:
12
3
2019
pubmed:
12
3
2019
medline:
17
6
2020
Statut:
epublish
Résumé
In tumors, extravascular fibrin forms provisional scaffolds for endothelial cell (EC) growth and motility during angiogenesis. We report that fibrin-mediated angiogenesis was inhibited and tumor growth delayed following postnatal deletion of Tgfbr2 in the endothelium of Cdh5-CreERT2 Tgfbr2fl/fl mice (Tgfbr2iECKO mice). ECs from Tgfbr2iECKO mice failed to upregulate the fibrinolysis inhibitor plasminogen activator inhibitor 1 (Serpine1, also known as PAI-1), due in part to uncoupled TGF-β-mediated suppression of miR-30c. Bypassing TGF-β signaling with vascular tropic nanoparticles that deliver miR-30c antagomiRs promoted PAI-1-dependent tumor growth and increased fibrin abundance, whereas miR-30c mimics inhibited tumor growth and promoted vascular-directed fibrinolysis in vivo. Using single-cell RNA-Seq and a NanoString miRNA array, we also found that subtypes of ECs in tumors showed spectrums of Serpine1 and miR-30c expression levels, suggesting functional diversity in ECs at the level of individual cells; indeed, fresh EC isolates from lung and mammary tumor models had differential abilities to degrade fibrin and launch new vessel sprouts, a finding that was linked to their inverse expression patterns of miR-30c and Serpine1 (i.e., miR-30chi Serpine1lo ECs were poorly angiogenic and miR-30clo Serpine1hi ECs were highly angiogenic). Thus, by balancing Serpine1 expression in ECs downstream of TGF-β, miR-30c functions as a tumor suppressor in the tumor microenvironment through its ability to promote fibrin degradation and inhibit blood vessel formation.
Identifiants
pubmed: 30855280
pii: 123106
doi: 10.1172/JCI123106
pmc: PMC6436861
doi:
pii:
Substances chimiques
MicroRNAs
0
Mirn30d microRNA, mouse
0
Neoplasm Proteins
0
Plasminogen Activator Inhibitor 1
0
RNA, Neoplasm
0
Transforming Growth Factor beta
0
Receptor, Transforming Growth Factor-beta Type II
EC 2.7.11.30
Tgfbr2 protein, mouse
EC 2.7.11.30
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1654-1670Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES010126
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126974
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA213793
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA044579
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA177875
Pays : United States
Organisme : American Heart Association-American Stroke Association
ID : 15PRE24470053
Pays : United States
Références
J Clin Oncol. 2000 Feb;18(3):600-8
pubmed: 10653875
Blood Coagul Fibrinolysis. 2001 Jan;12(1):51-8
pubmed: 11229827
Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78
pubmed: 11252892
J Biol Chem. 2001 Sep 7;276(36):33964-8
pubmed: 11441025
Science. 2001 Aug 31;293(5535):1602-4
pubmed: 11533466
J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
pubmed: 11792750
Blood. 2002 Jul 15;100(2):560-8
pubmed: 12091349
Cancer Res. 2002 Dec 1;62(23):6966-72
pubmed: 12460914
Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43
pubmed: 12461559
Am J Pathol. 2003 Jun;162(6):1747-57
pubmed: 12759232
Nat Struct Biol. 2003 Jul;10(7):541-4
pubmed: 12808446
Cell. 2003 Jun 13;113(6):685-700
pubmed: 12809600
Blood. 2003 Oct 15;102(8):2819-27
pubmed: 12829586
Oncogene. 2003 Jul 10;22(28):4389-97
pubmed: 12853975
Microvasc Res. 2003 Sep;66(2):102-12
pubmed: 12935768
Science. 2004 Feb 6;303(5659):848-51
pubmed: 14764882
Nat Rev Cancer. 2005 Aug;5(8):591-602
pubmed: 16056258
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Cell. 2007 Jun;11(6):539-54
pubmed: 17560335
Annu Rev Pathol. 2007;2:251-75
pubmed: 18039100
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Nat Rev Mol Cell Biol. 2008 Aug;9(8):628-38
pubmed: 18628784
Cancer Cell. 2008 Sep 9;14(3):201-11
pubmed: 18772110
Cancer Cell. 2008 Oct 7;14(4):324-34
pubmed: 18835034
Circ Res. 2009 Jan 30;104(2):170-8, 6p following 178
pubmed: 19096030
Nat Med. 2009 Jan;15(1):68-74
pubmed: 19122658
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Curr Opin Genet Dev. 2009 Jun;19(3):205-11
pubmed: 19446450
PLoS Genet. 2010 Jan;6(1):e1000795
pubmed: 20062521
Blood. 2010 Nov 11;116(19):4025-33
pubmed: 20705756
Biochem J. 2011 Mar 15;434(3):473-82
pubmed: 21175428
Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006544
pubmed: 22355795
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006536
pubmed: 22393533
Breast Cancer Res. 2012 Aug 20;14(4):R120
pubmed: 22906178
PLoS One. 2012;7(8):e44532
pubmed: 22952991
J Natl Cancer Inst. 2012 Oct 3;104(19):1470-84
pubmed: 22984202
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
Blood. 2012 Dec 13;120(25):5063-72
pubmed: 23086751
EMBO J. 2013 Jan 23;32(2):219-30
pubmed: 23188081
Breast Cancer Res Treat. 2013 Jan;137(2):373-82
pubmed: 23224145
Nat Commun. 2013;4:1393
pubmed: 23340433
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Cell. 1990 Aug 10;62(3):435-45
pubmed: 2379237
Clin Cancer Res. 2013 Aug 15;19(16):4477-87
pubmed: 23797906
Hypertension. 2013 Sep;62(3):592-8
pubmed: 23817492
Mol Cancer Ther. 2013 Nov;12(11):2378-88
pubmed: 23990114
J Am Soc Nephrol. 2014 Jan;25(1):92-104
pubmed: 24029422
Mol Cancer Ther. 2013 Dec;12(12):2697-708
pubmed: 24072883
Angiogenesis. 2014 Jul;17(3):511-8
pubmed: 24257808
Cell. 2014 Feb 27;156(5):1002-16
pubmed: 24581498
Am Rev Respir Dis. 1989 Oct;140(4):1104-7
pubmed: 2478057
Nat Nanotechnol. 2014 Aug;9(8):648-655
pubmed: 24813696
Trends Genet. 2014 Jul;30(7):298-307
pubmed: 24929628
Nat Med. 2014 Jul;20(7):741-7
pubmed: 24929950
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3553-61
pubmed: 25114235
Cancer Biol Ther. 2015;16(2):253-60
pubmed: 25587663
Cancer Res. 2015 Apr 1;75(7):1244-54
pubmed: 25634211
Breast Cancer Res. 2014 Aug 22;16(4):428
pubmed: 25677449
Cancer Res. 2015 Aug 1;75(15):2969-74
pubmed: 26180080
PLoS One. 2015 Jul 24;10(7):e0133786
pubmed: 26207899
Nat Commun. 2015 Aug 12;6:7984
pubmed: 26264658
J Vis Exp. 2015 Oct 14;(105):e53072
pubmed: 26554446
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Res. 2016 Jun 1;76(11):3285-94
pubmed: 27197170
Sci Rep. 2016 Nov 07;6:36687
pubmed: 27819307
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):492-497
pubmed: 28034921
PLoS One. 2017 Oct 4;12(10):e0185619
pubmed: 28977001
Nat Methods. 2018 Apr;15(4):255-261
pubmed: 29481549
Nat Commun. 2018 Aug 7;9(1):3119
pubmed: 30087332
Am J Pathol. 1988 Mar;130(3):455-65
pubmed: 3279791
N Engl J Med. 1986 Dec 25;315(26):1650-9
pubmed: 3537791
J Natl Cancer Inst. 1981 Aug;67(2):335-45
pubmed: 6267343
Blood. 1994 Jun 1;83(11):3206-17
pubmed: 7514904
Exp Cell Res. 1993 Feb;204(2):356-63
pubmed: 7679998
Blood. 1996 Jun 1;87(11):4718-22
pubmed: 8639841
Cytokine Growth Factor Rev. 1997 Mar;8(1):21-43
pubmed: 9174661
EMBO J. 1998 Jun 1;17(11):3091-100
pubmed: 9606191
Nat Med. 1998 Aug;4(8):923-8
pubmed: 9701244